Фарицимаб

Rec. INN (наименование, зарегистрированное ВОЗ)

USAN (наименование, принятое к употреблению в США)

DB15303

N (не классифицировано FDA)

1607793-29-2

immunoglobulin G1-kappa/lambda with domain crossover, anti-[Homo sapiens VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)] and anti-[Homo sapiens ANGPT2 (angiopoietin 2, Ang2)], humanized and Homo sapiens monoclonal antibody, bispecific;
gamma1 heavy chain anti-VEGFA (1-453) [humanized VH (Homo sapiens IGHV3-30*02 (75.8%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.16] (1-123) -Homo sapiens IGHG1*01, G1m17,1 (CH1 K120 (220) (124-221), hinge 1-15 (222-236), CH2 [L1.3>A (240), L1.2>A (241), I15.2>A (259), H93>A (316), P114>G (335)] (237-346), CH3 D12 (362), L14 (364) [S10>C (360), T22>W (372), H115>A (441)] (347-451), CHS (452-453)) (124-453)], (226-214')-disulfide with kappa light chain, anti-VEGFA (1’-214’) [humanized V-KAPPA (Homo sapiens IGKV1-16*01 (87.4%) -IGKJ1*01 (100%)) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')];
gamma1-kappa heavy chain anti-ANGPT2 (1''-463'') [Homo sapiens VH (IGHV1-2*02 (100%) -(IGHD)-IGHJ3*02 (100%)) [8.8.22] (1''-129'') -Homo sapiens IGKC*01, Km3 A45.1 (175), V101 (213) [R1.4>A (130), T1.3>S (131)] (130''-236'') -Homo sapiens IGHG1*01, G1m1 (hinge 6-15 (237-246), (CH2 [L1.3>A (250), L1.2>A (251), I15.2>A (269), H93>A (326), P114>G (345)] (247-356), CH3 D12 (372), L14 (374) [Y5>C (365), T22>S (382), L24>A (384), Y86>V (423), H115>A (451)] (357-461), CHS (462-463)) (237''-463'')], (236''-213''')-disulfide with lambda-gamma light chain anti-ANGPT2 (1'''-213''') [Homo sapiens V-LAMBDA (IGLV3-21*02 (100.00%) -IGLJ2*01 (100%)) [6.3.11] (1'''-108''') -2-mer linker biseryl (109'''-110''') -Homo sapiens IGHG1*01, G1m17 (CH1 K120 (207) (111-208) -hinge 1-5 (209-213)) (111'''-213''')]; dimer (232-242":235-245":360-365")-trisdisulfide;

Поделиться этой страницей